According to Market.us, the global market size for alpha-1 antitrypsin deficiency augmentation therapy is projected to reach approximately USD 2,517 million by 2032, up from USD 1,413 million in 2022.

The global alpha-1 antitrypsin deficiency (AATD) market is expanding, driven by advances in diagnosis, treatment, and growing awareness. Key players ...

Researchers report on the safety of a gene therapy to treat the common autosomal recessive hereditary disorder alpha 1-antitrypsin (AAT) deficiency in a new article in Human Gene Therapy.

According to Market.us, the global alpha-1 antitrypsin deficiency augmentation therapy market growth is driven by the increase in the prevalence of Genetic and Respiratory diseases and modern ...

Alpha-1 is a microcosm of the rare disease world. The challenges we face, late diagnoses, inconsistent care, and unaffordable ...

Alpha-1 Antitrypsin Deficiency Companies are Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZeneca, Inhibrx, Novo Nordisk, and others. (Albany, USA) DelveInsight ...

delivery and alpha-1 antitrypsin (AAT) expression within the respiratory tract following KB408 administration as well as safety and tolerability data for both KB407 and KB408 that, taken together ...

BEAM-302 demonstrated safety and efficacy in increasing AAT levels and reducing mutant protein in alpha-1 antitrypsin ... BEAM-302 has the potential to be a one-time therapy that ...

Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why ...

First, 1) BEAM-101 for sickle cell disease [SCD], 2) BEAM-302 for alpha-1 antitrypsin deficiency [AATD], and 3) BEAM-301 for glycogen storage disease type Ia [GSDIa].

Beam Therapeutics Inc. (NASDAQ:BEAM) has secured U.S. FDA orphan drug designation for BEAM-302, its pioneering genetic medicine targeting alpha-1 antitrypsin deficiency (AATD), a rare inherited ...

The global alpha-1 antitrypsin deficiency (AATD) market is expanding, driven by advances in diagnosis, treatment, and growing awareness. Key players like Grifols, CSL Behring, and Pfizer lead ...